RPRX · Insider Trading
Royalty Pharma plc Class A Ordinary Shares
Every open-market purchase and sale reported by RPRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Marshall Urist | EVP, Research & Investments | Sell | −4,126 | −$235.59K |
| 2026-09-30 | Marshall Urist | EVP, Research & Investments | Sell | −4,126 | −$238.81K |
| 2026-09-30 | Bonnie L Bassler | Director | A | +642 | +$37.50K |
| 2026-09-24 | Christopher Hite | EVP & Chairman, Partnering | Sell | −100,000 | −$5.85M |
| 2026-08-19 | Christopher Hite | EVP & Chairman, Partnering | MIXED | −116,800 | −$6.00M |
| 2026-08-17 | Terrance P. Coyne | EVP & CFO | Sell | −11,002 | −$645.55K |
| 2026-08-07 | Christopher Hite | EVP & Chairman, Partnering | A | +11,002 | — |
| 2026-08-07 | Marshall Urist | EVP, Research & Investments | A | +8,252 | — |
| 2026-08-07 | Pablo G. Legorreta | CEO, Chairman of the Board | A | +65,216 | — |
| 2026-08-07 | Terrance P. Coyne | EVP & CFO | A | +11,002 | — |
| 2026-08-07 | Marshall Urist | EVP, Research & Investments | A | +8,252 | — |
| 2026-08-07 | Terrance P. Coyne | EVP & CFO | A | +11,002 | — |
| 2026-08-07 | Pablo G. Legorreta | CEO, Chairman of the Board | A | +65,216 | — |
| 2026-08-07 | Christopher Hite | EVP & Chairman, Partnering | A | +11,002 | — |
| 2026-07-02 | Christopher Hite | EVP & Chairman, Partnering | Sell | −130,000 | −$7.35M |
| 2026-07-02 | Marshall Urist | EVP, Research & Investments | Sell | −9,099 | −$508.45K |
| 2026-06-25 | Marshall Urist | EVP, Research & Investments | Sell | −9,098 | −$502.07K |
| 2026-06-25 | Christopher Hite | EVP & Chairman, Partnering | Sell | −150,000 | −$8.16M |
| 2026-06-08 | David C Hodgson | Director | A | +4,545 | — |
| 2026-06-08 | Ted W Love | Director | A | +4,545 | — |
| 2026-06-08 | Carole Ho | Director | A | +4,545 | — |
| 2026-06-08 | Gregory Norden | Director | A | +4,545 | — |
| 2026-06-08 | Bonnie L Bassler | Director | A | +4,545 | — |
| 2026-06-08 | Catherine M. Engelbert | Director | A | +4,545 | — |
| 2026-06-08 | Vlad Coric | Director | A | +4,545 | — |
| 2026-06-08 | Elizabeth H Weatherman | Director | A | +4,545 | — |
| 2026-05-28 | Terrance P. Coyne | EVP & CFO | Sell | −64,399 | −$3.48M |
| 2026-05-21 | Marshall Urist | EVP, Research & Investments | Sell | −13,684 | −$721.84K |
| 2026-05-15 | Gregory Norden | Director | Sell | −3,045 | −$161.38K |
| 2026-05-15 | Marshall Urist | EVP, Research & Investments | Sell | −13,684 | −$726.14K |
| 2026-05-08 | Marshall Urist | EVP, Research & Investments | A | +18,197 | — |
| 2026-05-08 | Christopher Hite | EVP & Vice Chairman | A | +24,263 | — |
| 2026-05-08 | Terrance P. Coyne | EVP & CFO | A | +24,263 | — |
| 2026-05-08 | Pablo G. Legorreta | CEO, Chairman of the Board | A | +143,821 | — |
| 2026-04-30 | Terrance P. Coyne | EVP & CFO | Sell | −34,791 | −$1.73M |
| 2026-04-02 | Terrance P. Coyne | EVP & CFO | Sell | −34,791 | −$1.68M |
| 2026-03-31 | Bonnie L Bassler | Director | A | +815 | +$37.47K |
| 2026-03-25 | Terrance P. Coyne | EVP & CFO | Sell | −34,791 | −$1.58M |
| 2026-03-04 | Terrance P. Coyne | EVP & CFO | Sell | −34,791 | −$1.63M |
| 2026-02-25 | Terrance P. Coyne | EVP & CFO | Sell | −34,791 | −$1.58M |
| 2026-02-13 | Marshall Urist | EVP, Research & Investments | A | +19,970 | — |
| 2026-02-13 | Christopher Hite | EVP & Vice Chairman | A | +26,626 | — |
| 2026-02-13 | Terrance P. Coyne | EVP & CFO | A | +26,626 | — |
| 2026-02-13 | Pablo G. Legorreta | CEO, Chairman of the Board | A | +157,828 | — |
| 2026-02-04 | Terrance P. Coyne | EVP & CFO | Sell | −243,541 | −$10.36M |
| 2026-02-02 | Marshall Urist | EVP, Research & Investments | Sell | −20,000 | −$821.81K |
| 2026-01-26 | Marshall Urist | EVP, Research & Investments | Sell | −20,000 | −$805.11K |
| 2026-01-23 | Terrance P. Coyne | EVP & CFO | Sell | −69,582 | −$2.74M |
| 2026-01-20 | Marshall Urist | EVP, Research & Investments | Sell | −20,000 | −$790.35K |
| 2026-01-13 | Marshall Urist | EVP, Research & Investments | Sell | −20,000 | −$815.63K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Pablo G. Legorreta | CEO, Chairman of the Board | 1,426,320 | $85.96M |
| George W. Lloyd | EVP, Investments & CLO | 496,090 | $29.90M |
| Christopher Hite | EVP & Chairman, Partnering | 293,601 | $17.70M |
| Gregory Norden | Director | 196,348 | $11.83M |
| Henry A Fernandez | Director | 123,524 | $7.44M |
| Errol B Desouza | Director | 81,352 | $4.90M |
| Bonnie L Bassler | Director | 79,823 | $4.81M |
| Ted W Love | Director | 58,393 | $3.52M |
| Catherine M. Engelbert | Director | 55,673 | $3.36M |
| David C Hodgson | Director | 37,873 | $2.28M |
| Marshall Urist | EVP, Research & Investments | 19,020 | $1.15M |
| Vlad Coric | Director | 15,343 | $924.72K |
| Elizabeth H Weatherman | Director | 13,103 | $789.72K |
| Carole Ho | Director | 13,103 | $789.72K |
| Terrance P. Coyne | EVP & CFO | 1,500 | $90.41K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RPRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.